Norway
· Delayed Price · Currency is NOK Nykode Therapeutics AS Company Description
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.
The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10.
COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron.
Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
| Country | Norway |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 173 |
| CEO | Michael Engsig |
Contact Details
Address: Oslo Research Park Oslo, 0349 Norway | |
| Phone | 47 22 95 81 93 |
| Website | nykode.com |
Stock Details
| Ticker Symbol | NYKD |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | NO0010714785 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Thyring Engsig | Chief Executive Officer |
| Harald Gurvin | Chief Financial Officer |
| Ulrich Blaschke | Chief Technology Officer |
| Dr. Agnete B. Fredriksen Ph.D. | Chief Scientific Officer and Business Development |
| Louise Stubbe | Chief Legal Officer |
| Dr. Klaus Edvardsen M.D., Ph.D. | Chief Research and Development Officer |